Chemotherapy is currently not indicated for gastric cancers at a stage of less than T3 without LN metastasis.study was to determine the clinicopathological characteristics of and prognostic factors for LN-negative advanced gastric cancer (T2~4N0M0).
Materials and Methods
A total of 1,890 patients underwent curative gastrectomy for gastric adenocarcinoma at the Memorial Jin-Pok Kim Korea Gastric Cancer Center, Inje University Seoul Paik Hospital, between September 1998 and December 2008. Of these patients, our study retrospectively enrolled 254 patients who had primary node-negative gastric cancer, stage T2~4. The exclusion criteria included metachronous gastrointestinal cancer, a previous history of surgery for gastric cancer, and palliative surgery. The patients in our study did not receive systemic chemotherapy or radiotherapy before surgery.
All patients underwent radical gastrectomy with D2 LN dissection, as defined by the Japanese Gastric Cancer Association. For statistical analysis, receiver operating characteristic (ROC) analysis was used to determine the optimal cutoff values for continuous variables. Univariate associations were assessed by using logistic, Kaplan-Meier, and log-rank tests. Two multivariate analyses of the prognostic factors for recurrence were performed, one using logistic regression and the other using the Cox proportional hazards model.
The statistical analysis were performed using SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA).
Results

Incidence and patterns of recurrence
Our study included 254 patients who underwent curative surgery and whose pathologic diagnosis was node-negative advanced gastric cancer; 128 patients (50.4%), 88 patients (34.6%), 37 patients (14.6%), and 1 patient (0.4%) had T2, T3, T4a, and T4b tumors, respectively. Tumor recurrence occurred in 21 patients (8.3%) and was locoregional in 6 patients (28.6%), hematogenous in 6 patients (28.6%), peritoneal dissemination in 4 patients (19.0%), and multiple metastases in 5 patients (23.8%) ( (7) Locoregional (6) Hematogenous ( The current TNM system requires that a minimum of 15 LNs (cutoff value=15) be collected via standard gastrectomy. In our study cohort, the total number of resected LNs nodes was 11,270, and the median number of resected LNs was 43. Less than 15
LNs were resected in only 11 patients (4.3%; the LN<15 group).
Based on ROC analysis, the optimal cutoff value for dissected LNs was 38 (Fig. 2) . In our study cohort, 84 patients (33.1%) had less than 38 resected LNs (the LN<38 group) and 170 patients (66.9%) had more than 38 resected LNs (the LN≥38 group). Tumors recurred in 4 patients (57.1%) in the LN<15 group, 17 patients (7.52%) in the LN≥15 group, 8 patients (10.5%) in the LN<38 group, and 13 patients (8.2%) in the LN≥38 group (Table 1) . 
Analysis of clinicopathologic factors and recurrence
Overall survival of patients with node-negative advanced gastric cancer
In a multivariate analysis using logistic regression, cumulative overall survival (OS) was significantly associated with operation type (P=0.043), T-stage (P=0.026), venous invasion (P=0.016), tumor size (P=0.024), and LN number<15 (P<0.001), but not LN number<38 (Fig. 3) . In a multivariate analysis using the Cox proportional hazards model, cumulative OS was significantly associated with tumor size (P=0.021), venous invasion (P=0.010), and LN number<15 (P<0.001) ( Table 2 ). between the stage IIA gastric cancer subgroups. 10 The decision to administer adjuvant chemotherapy to patients withT3N0 gastric cancer is currently left to the clinicians' discretion. This study, which examined T2~4N0 gastric cancers, found that T-stage was a significant prognostic factor for recurrence and OS in a univariate analysis, but not a multivariate analysis using the Cox proportional hazards model.
Among the various prognostic factors previously reported, tumor size is especially important in node-negative advanced gastric cancer. Adachi et al. 11 identified gastric tumor size as a simple prognostic indicator. Kim et al. 12 found that patients with nodenegative gastric cancers had favorable outcomes, whereas those with relatively large tumors and serosal invasion had unfavorable outcomes. Yokota et al. 13 showed that tumor size predicted survival rates in patients with gastric cancer. Our study shows that gastric tumor size and prognosis are closely associated.
In the study by Zhang et al, 14 the number of retrieved LNs was an independent prognostic factor in node-negative gastric can- 17 and the comparative analysis by Lee et al. 18 of patients with N0 versus N1 gastric cancer. In our study, however, there was no significant relationship between venous invasion and lymphatic invasion. Furthermore, venous invasion correlated significantly with OS and recurrence, whereas lymphatic invasion did not. These findings may reflect our study's focus on node-negative patients only.
In conclusion, we recommend the development of comprehensive, individualized treatment plans for patients with nodenegative gastric cancer. Our analysis of these cancers showed that tumor size, venous invasion, and at least 15 retrieved LNs were independent prognostic indicators of survival. Further evaluation of prognostic factors is needed to determine whether treatments such as adjuvant therapy benefit patients with node-negative advanced gastric cancer.
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